{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003947846,0.0002297011,0.0005769889,0.0001234628,0.000147627,0.0003066273,0.0001233999,0.0003210213,0.001566908],"category_scores_gemma":[0.0006612017,0.0001355683,0.000469835,0.0001948313,0.0001434159,0.0003400524,0.0001645006,0.0006619078,0.0001896326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003215104,"about_ca_system_score_gemma":0.0005084988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001003626,"about_ca_topic_score_gemma":0.003157464,"domain_scores_codex":[0.9998679,0.00004903594,0.00001038608,0.00002599222,0.00001390216,0.00003274501],"domain_scores_gemma":[0.9998267,0.00004153461,0.00003372479,0.00000613019,0.000009430768,0.00008252216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6073079,0.006694918,0.154961,0.0009012391,0.001417384,0.0008311414,0.0002000014,0.001696397,0.01626725,0.0002800605,0.003291488,0.2061512],"study_design_scores_gemma":[0.05777522,0.3429145,0.5718543,0.0003339516,0.003385122,0.001577719,0.0004180889,0.003500742,0.004169622,0.0005625186,0.01345652,0.00005171862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954596,0.002681089,0.00008095397,0.0002006925,0.0000834859,0.00006045891,0.000119724,0.000008097578,0.001305787],"genre_scores_gemma":[0.9978865,0.0009171746,0.0001501503,0.0001412237,0.00005003075,0.00004069442,0.0001702241,0.000001651589,0.0006423782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001566908,"threshold_uncertainty_score":0.005241871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008630389719972233,"score_gpt":0.2672043473917885,"score_spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}